{
  "id": 16749549,
  "title": "STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more",
  "url": "https://urgent.news/2026/10/27/stat-pharmalittle-were-reading-about-a-novo-setback-in-court-a-house",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T13:25:50.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/10/27/novo-setback-in-court-house-probe-into-big-pbms/"
  },
  "original_language": "en",
  "account": "Novo's setback in court, House probe into PBMs, and other news dominate Pharmalot today. GSK is seeing its oncology business start to thrive, with recent approvals and a licensed medicine getting attention at an oncology conference. However, GSK still lags behind the sales of Merck's Keytruda. Meanwhile, a House lawmaker is investigating the three largest pharmacy benefit managers for allegedly targeting independent pharmacies with audits after they backed legislation that would require adjustments to payments to the retailers.",
  "summary": "A U.S. judge rejected a bid to block Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}